Imatinib-resistance without BCR/ABL Point Mutation in Chronic Myeloid Leukemia
Chronic myeloid leukemia (CML) is a myeloproliferative bone marrow neoplasm that occurs because of a fusion gene called BCR-ABL1. Imatinib -the inhibitor of this fusion geneis the target therapy in CML. But unfortunately, resistance against imatinib occurs in some patients. In September 2019 47-year...
Guardat en:
| Autor principal: | |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Azerbaijan Gastroenterology and Invasive Endoscopy Society
2024-03-01
|
| Col·lecció: | Caucasian Medical Journal |
| Matèries: | |
| Accés en línia: | https://caucasianmedj.com/articles/imatinib-resistance-without-bcrabl-point-mutation-in-chronic-myeloid-leukemia/doi/cmj.galenos.2024.36855 |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|